Update shared on 21 Nov 2025
Fair value Decreased 0.81%Analysts have slightly reduced their fair value price target for MedinCell from $35.16 to $34.87, reflecting tempered expectations around revenue growth and profit margins.
What's in the News
- MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which may enhance visibility among institutional investors and index-tracking funds. This change is effective 24 November 2025 (Key Developments).
- Teva Pharmaceuticals and MedinCell received FDA approval for UZEDY® (risperidone) as a once-monthly extended-release injectable for maintenance treatment of bipolar I disorder in adults (Key Developments).
- MedinCell plans to submit a New Drug Application for Olanzapine LAI, a once-monthly subcutaneous long-acting injection for schizophrenia, in the US in the fourth quarter of 2025 (Key Developments).
- UZEDY® gained regulatory approval in South Korea. Global sales reached $117 million in 2024 and $95 million in the first half of 2025. MedinCell earns mid- to high-single digit royalties on sales (Key Developments).
Valuation Changes
- Fair Value Price Target has decreased slightly from €35.16 to €34.87, reflecting a modest downward revision.
- Discount Rate remains unchanged at 6.18%.
- Revenue Growth forecast has fallen significantly from 74.30% to 68.61%.
- Net Profit Margin estimate has dropped markedly from 58.71% to 47.91%.
- Future P/E Ratio has risen from 19.53x to 21.64x. This indicates higher expected valuation multiples relative to earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.